Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Interaction of MRE11 and Clinicopathologic Characteristics in Recurrence of Breast Cancer: Individual and Cumulated Receiver Operating Characteristic Analyses.

Yang CH, Moi SH, Chuang LY, Yuan SF, Hou MF, Lee YC, Chang HW.

Biomed Res Int. 2017;2017:2563910. doi: 10.1155/2017/2563910. Epub 2017 Jan 4.

2.

Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.

Moi SH, Lee YC, Chuang LY, Yuan SF, Ou-Yang F, Hou MF, Yang CH, Chang HW.

Cancer Cell Int. 2018 Feb 9;18:19. doi: 10.1186/s12935-018-0517-z. eCollection 2018.

3.

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.

Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

Breast Cancer. 2016 Nov;23(6):830-843. Epub 2015 Oct 14.

4.

Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.

Le Goff JM, Lavayssière L, Rouëssé J, Spyratos F.

Anticancer Res. 2000 May-Jun;20(3B):2213-8.

PMID:
10928180
5.

Predicting axillary sentinel node status in patients with primary breast cancer.

Kolarik D, Pecha V, Skovajsova M, Zahumensky J, Trnkova M, Petruzelka L, Halaska M, Sottner O, Otcenasek M, Kolarova H.

Neoplasma. 2013;60(3):334-42. doi: 10.4149/neo_2013_045.

PMID:
23374005
6.

18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.

Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, Lee J.

J Nucl Med. 2012 Sep;53(9):1337-44. doi: 10.2967/jnumed.111.098640. Epub 2012 Jun 29.

7.

Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy.

Niméus-Malmström E, Krogh M, Malmström P, Strand C, Fredriksson I, Karlsson P, Nordenskjöld B, Stål O, Ostberg G, Peterson C, Fernö M.

Breast Cancer Res. 2008;10(2):R34. doi: 10.1186/bcr1997. Epub 2008 Apr 22.

8.

Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.

Park YH, Im SA, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh DY, Yang JH, Ahn JS, Im YH.

Oncology. 2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.

PMID:
24903080
9.

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

10.

Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.

Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T, Okada M.

Breast. 2013 Oct;22(5):958-63. doi: 10.1016/j.breast.2013.05.003. Epub 2013 Jun 10.

PMID:
23756383
11.

Population-based molecular prognosis of breast cancer by transcriptional profiling.

Ma Y, Qian Y, Wei L, Abraham J, Shi X, Castranova V, Harner EJ, Flynn DC, Guo L.

Clin Cancer Res. 2007 Apr 1;13(7):2014-22.

12.

Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.

Rohan TE, Xue X, Lin HM, D'Alfonso TM, Ginter PS, Oktay MH, Robinson BD, Ginsberg M, Gertler FB, Glass AG, Sparano JA, Condeelis JS, Jones JG.

J Natl Cancer Inst. 2014 Jun 3;106(8). pii: dju136. doi: 10.1093/jnci/dju136. Print 2014 Aug.

13.

Predicting local recurrence following breast-conserving treatment: parenchymal signal enhancement ratio (SER) around the tumor on preoperative MRI.

Kim MY, Cho N, Koo HR, Yun BL, Bae MS, Chie EK, Moon WK.

Acta Radiol. 2013 Sep;54(7):731-8. doi: 10.1177/0284185113483676. Epub 2013 Apr 30.

PMID:
23550189
14.

New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients.

Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS; Bay Area SLN Study.

BMC Cancer. 2008 Mar 4;8:66. doi: 10.1186/1471-2407-8-66.

15.

A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.

Schipper RJ, Moossdorff M, Nelemans PJ, Nieuwenhuijzen GA, de Vries B, Strobbe LJ, Roumen RM, van den Berkmortel F, Tjan-Heijnen VC, Beets-Tan RG, Lobbes MB, Smidt ML.

Clin Breast Cancer. 2014 Oct;14(5):315-22. doi: 10.1016/j.clbc.2013.12.015. Epub 2014 Jan 3.

PMID:
24548732
16.

Predicting breast cancer recurrence following breast-conserving therapy: a single-institution analysis consisting of 764 Chinese breast cancer cases.

Li S, Yu KD, Fan L, Hou YF, Shao ZM.

Ann Surg Oncol. 2011 Sep;18(9):2492-9. doi: 10.1245/s10434-011-1626-2. Epub 2011 Mar 1.

PMID:
21360247
17.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
18.

Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer.

Mitra AP, Lam LL, Ghadessi M, Erho N, Vergara IA, Alshalalfa M, Buerki C, Haddad Z, Sierocinski T, Triche TJ, Skinner EC, Davicioni E, Daneshmand S, Black PC.

J Natl Cancer Inst. 2014 Oct 24;106(11). pii: dju290. doi: 10.1093/jnci/dju290. Print 2014 Nov.

19.

Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.

Nakajima N, Kataoka M, Sugawara Y, Ochi T, Kiyoto S, Ohsumi S, Mochizuki T.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):738-46. doi: 10.1016/j.ijrobp.2013.08.001. Epub 2013 Sep 21.

PMID:
24064322
20.

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY.

BMC Cancer. 2008 Oct 23;8:307. doi: 10.1186/1471-2407-8-307.

Supplemental Content

Support Center